EHC Quote, Financials, Valuation and Earnings

HCA Healthcare has a net margin of 10.41% compared to Encompass Health's net margin of 8.79%. Encompass Health's return on equity of 18.4% beat HCA Healthcare's return on equity of 822.75%.

Encompass Health has a consensus price target of $130.09, signalling upside risk potential of 10.74%. On the other hand HCA Healthcare has an analysts' consensus of $371.84 which suggests that it could grow by 3.01%. Given that Encompass Health has higher upside potential than HCA Healthcare, analysts believe Encompass Health is more attractive than HCA Healthcare.

Encompass Health has a beta of 0.930, which suggesting that the stock is 7.02% less volatile than S&P 500. In comparison HCA Healthcare has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.86%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.56%. HCA Healthcare offers a yield of 0.75% to investors and pays a quarterly dividend of $0.72 per share. Encompass Health pays 13.78% of its earnings as a dividend. HCA Healthcare pays out 11.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are smaller than HCA Healthcare quarterly revenues of $18.3B. Encompass Health's net income of $151.5M is lower than HCA Healthcare's net income of $1.6B. Notably, Encompass Health's price-to-earnings ratio is 24.27x while HCA Healthcare's PE ratio is 16.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 2.18x versus 1.30x for HCA Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD has a net margin of 10.41% compared to Encompass Health's net margin of -156.54%. Encompass Health's return on equity of 18.4% beat Kindly MD's return on equity of -201.03%.

Encompass Health has a consensus price target of $130.09, signalling upside risk potential of 10.74%. On the other hand Kindly MD has an analysts' consensus of -- which suggests that it could fall by --. Given that Encompass Health has higher upside potential than Kindly MD, analysts believe Encompass Health is more attractive than Kindly MD.

Encompass Health has a beta of 0.930, which suggesting that the stock is 7.02% less volatile than S&P 500. In comparison Kindly MD has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.56%. Kindly MD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. Kindly MD pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are larger than Kindly MD quarterly revenues of $647.9K. Encompass Health's net income of $151.5M is higher than Kindly MD's net income of -$1M. Notably, Encompass Health's price-to-earnings ratio is 24.27x while Kindly MD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 2.18x versus 6.50x for Kindly MD. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of 10.41% compared to Encompass Health's net margin of 4.52%. Encompass Health's return on equity of 18.4% beat Pediatrix Medical Group's return on equity of -10.7%.

Encompass Health has a consensus price target of $130.09, signalling upside risk potential of 10.74%. On the other hand Pediatrix Medical Group has an analysts' consensus of $17.79 which suggests that it could grow by 23.94%. Given that Pediatrix Medical Group has higher upside potential than Encompass Health, analysts believe Pediatrix Medical Group is more attractive than Encompass Health.

Encompass Health has a beta of 0.930, which suggesting that the stock is 7.02% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.315%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.56%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are larger than Pediatrix Medical Group quarterly revenues of $458.4M. Encompass Health's net income of $151.5M is higher than Pediatrix Medical Group's net income of $20.7M. Notably, Encompass Health's price-to-earnings ratio is 24.27x while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 2.18x versus 0.61x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of 10.41% compared to Encompass Health's net margin of -13.15%. Encompass Health's return on equity of 18.4% beat The Oncology Institute's return on equity of -220.55%.

Encompass Health has a consensus price target of $130.09, signalling upside risk potential of 10.74%. On the other hand The Oncology Institute has an analysts' consensus of -- which suggests that it could fall by -23.37%. Given that Encompass Health has higher upside potential than The Oncology Institute, analysts believe Encompass Health is more attractive than The Oncology Institute.

Encompass Health has a beta of 0.930, which suggesting that the stock is 7.02% less volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.56%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are larger than The Oncology Institute quarterly revenues of $100.3M. Encompass Health's net income of $151.5M is higher than The Oncology Institute's net income of -$13.2M. Notably, Encompass Health's price-to-earnings ratio is 24.27x while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 2.18x versus 0.50x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.